Business Context and Reporting Period
On January 31, 2020, Amneal Pharmaceuticals, Inc. (the "Company") consummated the acquisition of approximately 65% of AvKARE Inc. and Dixon-Shane, LLC d/b/a R&S Northeast LLC (collectively, the "Target"). The transaction was executed through Rondo Acquisition LLC, a wholly-owned subsidiary of the Company.
Key Financial Metrics and Transaction Details
- Total Consideration: Approximately $255 million paid in cash at or in connection with closing.
- Financing Structure:
- Debt Facilities: $210 million in senior secured first lien credit facilities, comprising a $30 million revolving credit facility and a $180 million term loan facility.
- Sellers Notes: $44.2 million in long-term promissory notes issued to Target shareholders.
- Ownership Structure: The Company owns approximately 65% of Rondo Partners, LLC (the indirect owner of the Target). Former Target shareholders ("Rollover Sellers") contributed cash received at closing in exchange for approximately 35% ownership in Rondo Partners.
- Debt Terms:
- Sellers Notes Interest: 5% per annum, non-compounded, until June 30, 2025.
- Term Loan Amortization: Quarterly payments of $2.25 million beginning June 30, 2020.
- Maturity: Term loans mature on January 31, 2025; Sellers Notes mature on January 31, 2030 (or earlier upon change of control).
Material Changes and Covenants
The filing details the entry into material definitive agreements and the creation of direct financial obligations. The Company has incurred significant new debt to fund the acquisition. The Credit Agreement imposes the following financial covenants, calculated as of the last day of each fiscal quarter:
- Total Net Leverage Ratio: Must be less than or equal to 4.50 to 1.00.
- Interest Coverage Ratio: Must be greater than or equal to 2.00 to 1.00.
Failure to meet these covenants or other events of default may result in the acceleration of debt obligations and an increase in interest rates by 200 basis points.
Outlook, Risks, and Unusual Items
Management Commentary and Future Filings: The Company intends to file financial statements of the acquired business and pro forma financial information within the time periods permitted by Regulation S-X and Article 11 of Regulation S-X, respectively. No specific revenue or profit guidance for the combined entity was provided in this filing.
Risks and Contingencies:
- Liquidity Risk: The Company is subject to strict debt service requirements and leverage covenants.
- Collateral: All obligations under the Credit Agreement are secured by a first-priority lien on substantially all tangible and intangible assets of the Loan Parties, including intellectual property and equity interests.
- Change of Control: Sellers Notes become immediately payable upon a sale or change of control of the obligor.
Investor Verification Checklist
- Verify the pro forma financial impact of the $255 million acquisition on the Company's balance sheet and leverage ratios.
- Confirm the Company's ability to meet the 4.50:1.00 Total Net Leverage Ratio and 2.00:1.00 Interest Coverage Ratio covenants immediately post-closing.
- Review the upcoming filings for the acquired business's historical financial statements to assess the quality of earnings and cash flow of the Target.
- Monitor the $2.25 million quarterly principal payments on the term loan commencing June 30, 2020.
- Assess the implications of the 35% ownership retained by Rollover Sellers on future governance and potential exit strategies.